Pharming Reports Q2 GAAP EPS of $0.00 and Revenue Misses Estimates
Pharming (PHAR:NASDAQ) reported a second-quarter 2026 GAAP earnings per share (EPS) of $0.00, missing the expected figure by $0.06. The company also recorded revenue of $90.2 million for Q2, which fell short of estimates by $9.32 million and marked a year-over-year decline of 3.2%. This represents a decrease from the second quarter of 2025 when revenues stood at $93.2 million. The results highlight challenges in maintaining revenue growth amid competitive pressures or market conditions affecting its operations. The earnings miss could raise concerns among investors about Pharming's ability to meet financial targets and sustain performance improvements seen previously.
Tickers: $PHAR
Topics: earnings pharma revenue miss